Managing the scourge of diabetes is a never-ending battle, but a Richmond, Virginia-based treatment company has achieved a noteworthy conquest for its product.
ALR Technologies, Inc. (OTCPINK:ALRT) announced Tuesday it had signed an agreement with Singapore General Hospital (“SGH”) to undertake jointly a novel remote diabetes management pilot to prove the efficacy of the ALRT Diabetes Solution in insulin-treated diabetes patients.
This is significant because Singapore has the second-highest proportion of diabetics among developed nations according to the International Diabetes Federation.
SGH will recruit 25 type 2 diabetes (“T2D”) patients who use premixed insulin and whose baseline A1C values are greater than 8% for the pilot called GlucosE Monitoring and InterventioN in Insulin-treated T2D patients (GEMINI-T2D). The patients’ blood glucose data will be analyzed during the 24-week treatment period using the ALRT Diabetes Solution remote patient management platform. The study will determine the usefulness and feasibility of using ALRT diabetes management technology in managing T2D patients treated with premixed insulin.
ALRT shares climbed 7.2% to 2.9 cents by midday Tuesday, on volume topping 319,000